Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies

American Journal of Epidemiology

Volumn 166, Issue 5, 2007, Pages 552-560

  Wu, Tianying ^a   Willett, Walter C ^a,b   Rifai, Nader ^c   Rimm, Eric B ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Biological markers; Coronary disease; Epidemiologic studies; Fluorescence; Oxidation reduction; Oxidative stress; Plasma; Risk factors

Indexed keywords

BIOLOGICAL MARKER; FLUORESCENT OXIDATION PRODUCT; UNCLASSIFIED DRUG;

BIOMARKER; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; HEALTH RISK; HYPERTENSION; MULTIVARIATE ANALYSIS; OXIDATION; QUESTIONNAIRE SURVEY; REDUCTION; RISK FACTOR; SMOKING;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PHYSICAL ACTIVITY; QUESTIONNAIRE; SMOKING; UNITED STATES;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; CREATININE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; INTERLEUKIN-6; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SMOKING; SPECTROMETRY, FLUORESCENCE; UNITED STATES;

NORTH AMERICA; UNITED STATES;

EID: 34548027028     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm119     Document Type: Article

References (62)

1. Pryor WA, ed. Free radicals in biology. New York, NY: Academic Press, 1980.
2. Frankel EN. Lipid oxidation. Dundee, Scotland: The Oily Press Ltd, 1998.
3. Liang JH, Lin CC. Fluorescence kinetics of soybean flour oxidation. J Am Oil Chem Soc 2000;77:709-13.
4. Liang J. Kinetics of fluorescence formation in whole milk powders during oxidation. Food Chem 2000;71:459-63.
5. Mohanakumar KP, de Bartolomeis A, Wu RM, et al. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation. Ann N Y Acad Sci 1994;738:392-9.
6. Sziraki I, Mohanakumar KP, Rauhala P, et al. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 1998;85:1101-11.
7. Shimasaki H. Assay of fluorescent lipid peroxidation products. Methods Enzymol 1994;233:338-46.
8. Iio T, Yoden K. Fluorescence formation from hydroperoxide of phosphatidylcholine with amino compound. Lipids 1988;23:65-7.
9. Dillard CJ, Tappel AL. Fluorescent products of lipid peroxidation of mitochondria and microsomes. Lipids 1971;6:715-21.
10. Wu T, Rifai N, Roberts LJ 2nd, et al. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomarkers Prev 2004;13:1399-402.
11. Dillard CJ, Tappel AL. Fluorescent damage products of lipid peroxidation. Methods Enzymol 1984;105:337-41.
12. Wu T, Rifai N, Willett WC, et al. Plasma fluorescent oxidation products: independent predictors of coronary heart disease among men. Am J Epidemiol 2007;166:000-00.
13. Mezzetti A, Zuliani G, Romano F, et al. Vitamin E and lipid peroxide plasma levels predict the risk of cardiovascular events in a group of healthy very old people. J Am Geriatr Soc 2001;49:533-7.
14. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
15. Frei B, Forte TM, Ames BN, et al. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 1991;277(pt 1):133-8.
16. Reilly M, Delanty N, Lawson JA, et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.
17. Chehne F, Oguogho A, Lupattelli G, et al. Increase of isoprostane 8-epi-PGF(2alpha)after restarting smoking. Prostaglandins Leukot Essent Fatty Acids 2001;64:307-10.
18. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
19. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95:588-93.
20. Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002;106:2800-5.
21. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002;346:1954-62.
22. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998;16:291-303.
23. Parslow RA, Sachdev P, Salonikas C, et al. Associations between plasma antioxidants and hypertension in a community-based sample of 415 Australians aged 60-64. J Hum Hypertens 2005;19:219-26.
24. Hozawa A, Ebihara S, Ohmori K, et al. Increased plasma 8-isoprostane levels in hypertensive subjects: the Tsurugaya Project. Hypertens Res 2004;27:557-61.
25. Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005;79:914-19.
26. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-16.
27. Lapolla A, Reitano R, Seraglia R, et al. Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 2005;49:685-90.
28. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
29. Nguyen AT, Lethias C, Zingraff J, et al. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985;28:158-67.
30. Ascherio A, Rimm EB, Giovannucci EL, et al. A prospective study of nutritional factors and hypertension among US men. Circulation 1992;86:1475-84.
31. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
33. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
34. Chasan-Taber S, Rimm EB, Stampfer MJ, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81-6.
35. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
36. Rifai N, Cole TG, Iannotti E, et al. Assessment of interlaboratory performance in external proficiency testing programs with a direct HDL-cholesterol assay. Clin Chem 1998;44:1452-8.
37. Siedel J, Schmuck R, Staepels J, et al. Long term stable, liquid ready-to-use monoreagent for the enzymatic assay of serum or plasma triglycerides (GPO-PAP method). AACC meeting abstract 34. Clin Chem 1993;39:1127.
38. Wahlefeld AW, Bergmeyer HU. Methods of enzymatic analysis. New York, NY: Academic Press Inc, 1974.
39. Rifai N, Iannotti E, DeAngelis K, et al. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. Clin Chem 1998;44:1242-50.
40. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994. Reference manuals and reports: manual for medical technicians and laboratory procedures used for NHANES III. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
41. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-25.
42. Self CH. Enzyme amplification - a general method applied to provide an immunoassisted assay for placental alkaline phosphatase. J Immunol Methods 1985;76:389-93.
43. Marz P, Cheng JG, Gadient RA, et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A 1998;95:3251-6.
44. Karl J, Burns G, Engel WD, et al. Development and standardization of a new immunoturbidimetric HbA1c assay. Klin Lab 1993;39:991-6.
45. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61.
46. Pryor WA, ed. Bio-assays for oxidative stress status (BOSS). Amsterdam, the Netherlands: Elsevier Science B V, 2001.
47. Pilz H, Oguogho A, Chehne F, et al. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb Res 2000;99:209-21.
48. Somers MJ, Mavromatis K, Galis ZS, et al. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000;101:1722-8.
49. Hishikawa K, Luscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 1997;96:3610-16.
50. Hishikawa K, Oemar BS, Yang Z, et al. Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res 1997;81:797-803.
51. Hsieh HJ, Cheng CC, Wu ST, et al. Increase of reactive oxygen species (ROS) in endothelial cells by shear flow and involvement of ROS in shear-induced c-fos expression. J Cell Physiol 1998;175:156-62.
52. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-9.
53. Murphey LJ, Morrow JD, Sawathiparnich P, et al. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. Free Radic Biol Med 2003;35:711-18.
54. Zager RA, Burkhart K. Myoglobin toxicity in proximal human kidney cells: roles of Fe, Ca2+, H2O2, and terminal mitochondrial electron transport. Kidney Int 1997;51:728-38.
55. Cvetkovic T, Vlahovic P, Pavlovic D, et al. Low catalase activity in rats with ureteral ligation: relation to lipid peroxidation. Exp Nephrol 1998;6:74-7.
56. Harper ME, Bevilacqua L, Hagopian K, et al. Ageing, oxidative stress, and mitochondrial uncoupling. Acta Physiol Scand 2004;182:321-31.
57. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
58. Roberts LJ 2nd, Reckelhoff JF. Measurement of F(2)-isoprostanes unveils profound oxidative stress in aged rats. Biochem Biophys Res Commun 2001;287:254-6.
59. Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002;156:274-85.
60. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:3230-5.
61. Reilly MP, Pratico D, Delanty N, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998;98:2822-8.
62. Roberts LJ, Morrow JD. Isoprostanes as markers of lipid peroxidation in atherosclerosis. In: Serhan CN, Ward PA, eds. Molecular and cellular basis of inflammation. Totawa, NJ: Humana Press, 1998:141-61.